- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00762736
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS™) in Combination With TAK-536 in Subjects With Type II Diabetes
Study Overview
Status
Conditions
Detailed Description
Diabetes is a chronic disease with multiple metabolic defects that result in hyperglycemia arising from inadequate insulin activity. Type 2 diabetes has a genetic predisposition, but lifestyle, body constitution and age play important roles in determining its time of onset and severity. Type 2 diabetes is usually the result of a progression from reduced sensitivity of hepatic and peripheral-tissue cells to circulating insulin (i.e., insulin resistance) to a progressive inability of the body to produce adequate insulin to overcome insulin resistance (i.e., insulin deficiency due to beta cell insufficiency) resulting in impaired glucose tolerance and ultimately overt diabetes. In the United States, an estimated 15.7 million people have diabetes, with type 2 diabetes occurring in approximately 90-95% of cases.
Therapeutic agents have been developed to address each of the major functional metabolic defects associated with type 2 diabetes: decreased beta-cell function, elevated hepatic glucose output, and insulin resistance. The oral therapeutic agents used in the treatment of type 2 diabetes can be separated into the following four categories based on their mechanisms of action: insulin secretagogues, inhibitors of hepatic glucose output, inhibitors of complex carbohydrate breakdown in the intestine and insulin sensitizers.
Thiazolidinediones reduce insulin resistance by enhancing insulin sensitivity in muscle cells, adipose tissue, and hepatic cells (inhibiting hepatic gluconeogenesis) with no direct impact on insulin secretion. Thus thiazolidinediones improve glycemic control and result in reduced levels of circulating insulin. Peroxisome proliferator-activated receptors are found in tissues important for insulin action, such as adipose tissue, skeletal muscle, and the liver. The greatest concentration of peroxisome proliferator-activated receptors -gamma receptors is in adipose tissue. Pioglitazone HCl (ACTOS®) is a thiazolidinedione developed by Takeda Chemical Industries, Ltd.
Research suggests that Angiotensin II receptor blockers are involved in endothelial and cardiovascular function, and in insulin sensitization and obesity. TAK-536 (azilsartan) is an angiotensin II receptor antagonist with affinity for and selective antagonistic activity at the angiotensin II type 1 receptor.
This study was designed to evaluate the efficacy, safety, and tolerability of pioglitazone in combination with azilsartan in subjects with type 2 diabetes.
Study participation is anticipated to be approximately 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
-
Cordoba, Argentina
-
Rosario-Santa Fe, Argentina
-
Santa Fe, Argentina
-
Ushuaia - Tierre del Fuego, Argentina
-
-
-
-
-
Santiago, Chile
-
-
-
-
-
Aguascalientes, Mexico
-
Cuernavaca, Mexico
-
Durango, Mexico
-
Guadalajara, Mexico
-
Mexico City, Mexico
-
Pueblo, Mexico
-
-
-
-
-
Ica, Peru
-
Lima, Peru
-
-
-
-
Alabama
-
Birmingham,, Alabama, United States
-
Huntsville, Alabama, United States
-
-
Arizona
-
Sierra Vista, Arizona, United States
-
Sun City, Arizona, United States
-
Tucson, Arizona, United States
-
-
California
-
Burbank, California, United States
-
Escondido, California, United States
-
Irvine, California, United States
-
La Jolla, California, United States
-
National City, California, United States
-
Riverside, California, United States
-
Sacramento, California, United States
-
San Diego, California, United States
-
Spring Valley, California, United States
-
-
Florida
-
Coral Gables, Florida, United States
-
Deland, Florida, United States
-
Hollywood, Florida, United States
-
Miami, Florida, United States
-
New Port Richey, Florida, United States
-
Opalocka, Florida, United States
-
Pembroke Pines, Florida, United States
-
Sarasota, Florida, United States
-
Vero Beach, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Augusta, Georgia, United States
-
Warner Robins, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
Lihue, Hawaii, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Dyersburg, Indiana, United States
-
-
Kansas
-
Overland Park, Kansas, United States
-
Wichita, Kansas, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
Shreveport, Louisiana, United States
-
-
Massachusetts
-
Salisbury, Massachusetts, United States
-
-
Michigan
-
Cadillac, Michigan, United States
-
Detroit, Michigan, United States
-
Livonia, Michigan, United States
-
-
Missouri
-
Kansas City, Missouri, United States
-
St. Louis, Missouri, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
North Las Vegas, Nevada, United States
-
-
New Jersey
-
Berlin, New Jersey, United States
-
Blackwood, New Jersey, United States
-
Trenton, New Jersey, United States
-
-
New York
-
Albany, New York, United States
-
Kingston, New York, United States
-
-
North Carolina
-
Charlotte, North Carolina, United States
-
-
Ohio
-
Marion, Ohio, United States
-
-
Oklahoma
-
Clinton, Oklahoma, United States
-
Oklahoma City, Oklahoma, United States
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
-
Altoona, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
Scotland,, Pennsylvania, United States
-
-
Rhode Island
-
Woonsocket, Rhode Island, United States
-
-
South Carolina
-
Greer, South Carolina, United States
-
-
Texas
-
Arlington, Texas, United States
-
Dallas, Texas, United States
-
Fort Worth, Texas, United States
-
Midland,, Texas, United States
-
North Richard Hills, Texas, United States
-
San Antonio, Texas, United States
-
-
Washington
-
Renton, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Had type 2 diabetes, with a hemoglobin value of greater than or equal to 8.0% or less than 10.0% at Screening.
- Females of childbearing potential who were sexually active agreed to use adequate contraception, and were neither pregnant nor lactating from Screening throughout the duration of the study.
- Received antihypertensive therapy and must have been on a stable dose for a minimum of 8 weeks prior to Screening.
- Had clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory unless the results were deemed not clinically significant for inclusion into this study by the investigator or sponsor.
- Had been on stable diet and exercise program and oral anti-glycemic therapy including sulfonylurea or metformin for 8 weeks prior to Screening.
Exclusion Criteria:
- Had a hemoglobin value less than 8.0% or greater than 10.0% at Screening.
- Was taking an angiotensin II receptor blocker.
- Had uncontrolled hypertension defined as systolic blood pressure greater than 160 mm Hg and diastolic blood pressure greater than 100 mm Hg. - Had a systolic blood pressure less than or equal to 110 mm Hg and/or diastolic blood pressure less than or equal to 60 mm Hg.
Was taking or was expected to take the following medications:
- antidiabetic agents (other than sulfonylurea or metformin)
- tricyclic antidepressants
- monoamine oxidase inhibitors
- phenothiazines
- diet medications
- amphetamines or their derivatives
- lithium
- common cold medications with chronic use
- nonsteroidal anti-inflammatory drugs with chronic use (including aspirin greater than 325 mg/day or cyclooxygenase 2 inhibitors).
- Had unstable angina or heart failure of any etiology with functional class New York Heart Association III or IV.
- Had a history of myocardial infarction.
- Had clinically significant cardiac conduction defects (eg, second or third degree atrioventricular block, left bundle branch block, sick sinus syndrome, atrial fibrillation or flutter).
- Had secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
- Had a history of collagen vascular disorder (eg, systemic lupus erythematosus, scleroderma) within the last 5 years.
- Had a body mass index greater than 39 kg/m2.
- Had significant, moderate-to-severe renal dysfunction (creatinine greater than 2.4 mg/dL). If receiving metformin, a creatinine greater than 1.5 mg/dL for male subjects or greater than 1.4 mg/dL for female subjects led to exclusion.
- Had a history of drug abuse or a history of alcohol abuse within the past 2 years.
- Had a previous history of cancer, other than basal cell carcinoma, that had not been in remission for at least 5 years prior to the first dose of study drug.
- Had type 2 diabetes with clinically important retinopathy or peripheral or autonomic neuropathy.
- Had an alanine aminotransferase or aspartate aminotransferase level of greater than 2.5 times the upper limit of normal, active liver disease, or jaundice.
- Was participating in another investigational study or had participated in an investigational study within 30 days prior to randomization.
- Had any other serious disease or condition at Screening (or randomization) that might have compromised subject safety, affected life expectancy, or made it difficult to successfully manage and follow the subject according to the protocol.
- Was hypersensitive to angiotensin II receptor blockers.
- Was hypersensitive to thiazolidinediones.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pioglitazone 15 mg QD + Azilsartan 5 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
|
Experimental: Pioglitazone 15 mg QD + Azilsartan 40 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
|
Active Comparator: Pioglitazone 15 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
Other Names:
|
Experimental: Pioglitazone 45 mg QD + Azilsartan 5 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
|
Experimental: Pioglitazone 45 mg QD + Azilsartan 40 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
Other Names:
|
Active Comparator: Pioglitazone 45 mg QD
|
Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
Other Names:
Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in glycosylated hemoglobin.
Time Frame: Week 24 or Final Visit
|
Week 24 or Final Visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from Baseline in glycosylated hemoglobin.
Time Frame: Weeks 12, 16, 20, and 24 or Final Visit
|
Weeks 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in fasting plasma glucose.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in total cholesterol.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in high-density lipoprotein.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in low-density lipoprotein.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in triglycerides.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in body weight.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in systolic and diastolic blood pressure.
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in incidence of edema (peripheral).
Time Frame: Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Weeks 2, 4, 6, 8. 12, 16, 20, and 24 or Final Visit
|
Change from Baseline in microalbuminuria excretion.
Time Frame: Week 24 or Final Visit
|
Week 24 or Final Visit
|
Change from Baseline in high-sensitivity C-reactive protein.
Time Frame: Weeks 12 and 24 or Final Visit
|
Weeks 12 and 24 or Final Visit
|
Change from Baseline in matrix metalloproteinase-9.
Time Frame: Weeks 12 and 24 or Final Visit
|
Weeks 12 and 24 or Final Visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 01-04-TL-OPI-525
- U1111-1115-8992 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCCompletedType 2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on Pioglitazone and azilsartan
-
TakedaTerminatedDiabetes Mellitus, Type 2
-
TakedaTerminatedType 2 DiabetesUnited States, Argentina, Mexico, Chile, Peru
-
Lee's Pharmaceutical LimitedZhaoke (Guangzhou) Pharmaceutical LimitedCompletedBioequivalence of Two Azilsartan FormulationsHong Kong
-
Lee's Pharmaceutical LimitedCompleted
-
Dong-A ST Co., Ltd.CompletedType 2 DiabetesKorea, Republic of
-
Solvay PharmaceuticalsCompletedType 2 Diabetes MellitusUnited Kingdom
-
Hospital General de México Dr. Eduardo LiceagaUnknownHypertension | Obesity | Type 2 Diabetes MellitusMexico
-
TakedaCompleted
-
University of ChicagoTakedaCompleted
-
Emory UniversityCompletedDiabetic Ketoacidosis | Ketosis Prone Diabetes | Severe HyperglycemiaUnited States